Date: October 19, 2021
Time: 8:00 a.m. CET
Poster #120: “EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19”
Presenter: Li-Juan Jiang, Ph.D.
Posters will be available to view on the conference platform during the conference and for three months thereafter.
More Information About Enanta Pharmaceuticals
Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), and SARS-CoV-2 (COVID-19).
Enanta is also conducting research in human metapneumovirus (hMPV).
Enanta research and development activities are funded by royalties from hepatitis C virus (HCV) products developed in collaboration with AbbVie.
Glacaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir).
For more information, please visit www.enanta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005607/en/
Media and Investor Contact
Source: Enanta Pharmaceuticals, Inc.
Enanta Therapeutics is in the Prohost Portfolio and we have no intention of abandoning it. Enanta has solid scientific fundamentals with promising products and a history of great achievements.
Clilck here to read more about Enanta Pharmaceuticals.
Don’t Miss the Enanta Pharmaceuticals Virtual Conference on October 19th – October 21st
Don’t Miss Enanta Pharmaceuticals Virtual Conference
Enanta Pharmaceuticals (ENTA) – a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data for EDP-235 – its lead oral protease inhibitor, which is specifically designed for the treatment of COVID-19, will be presented at the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)-World Health Organization Virtual Conference (WHO): COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment.
To read more information about the ISIRV-WHO Virtual Conference 2021, please click here.
The conference is being held virtually on October 19 – October 21, 2021.